Journal
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
Volume 50, Issue 4, Pages -Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/03000605221094274
Keywords
Sintilimab; rapid progression; immune checkpoint inhibitor; heterogeneity; lesion; metastasis; cancer; biopsy; treatment cycle; abraxane
Ask authors/readers for more resources
There is heterogeneity in cancer patients' responses to immune checkpoint inhibitors (ICIs), including hyperprogression and pseudoprogression. This heterogeneity complicates clinical decisions. This study presents two cases that highlight the importance of biopsy examination when subcutaneous nodules appear after treatment with ICIs.
There is heterogeneity in cancer patients' responses to immune checkpoint inhibitors (ICIs), including hyperprogression, which is very rapid tumor progression following immunotherapy, and pseudoprogression, which is an initial increase followed by a decrease in tumor burden or in the number of tumor lesions. This heterogeneity complicates clinical decisions because either premature withdrawal of the treatment or prolonged ineffective treatment harms patients. We presented two patients treated with ICIs with heterogeneous responses. One patient had Merkel cell carcinoma in the right thigh, and the other had nasopharyngeal squamous carcinoma. The first patient was treated with sintilimab and the second with sintilimab combined with abraxane. In the first patient, subcutaneous lesions grew substantially after the first cycle of treatment with sintilimab. In the second patient, subcutaneous lesions grew gradually after the second cycle of treatment with sintilimab combined with abraxane. In both cases, biopsy examination confirmed that newly emerged lesions were metastases of the primary tumor. These two cases remind clinicians that when subcutaneous nodules appear after treatment with ICIs, pathological biopsy is needed to determine the nature-pseudoprogression or rapid progression-of the disease course.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available